INTRODUCTION
Over the past 20 years suxamethonium has been in widespread use in clinical anaesthesia. Its unique properties have made it invaluable for use in emergency surgery and in procedures where profound short-term relaxation is required. Clinicians and research workers have studied it widely because of its interesting physiological implications and its dramatic pharmacological effects. The object of this review is to extract from the mass of knowledge accumulated by these workers useful information not readily obtainable from standard textbooks. In addition, an attempt will be made to reassess the place of suxamethonium in anaesthetic practice today, taking into account on the one hand its extensive use, and on the other hand the disturbing number of serious side-effects which have followed its administration. HISTORY In 1906 Hunt and Taveaux studied the biological properties of 19 choline derivatives, 17 of which had been recently synthesized for the first time. One of these new compounds was "succinyl-cholin".
They showed little interest in its properties, simply stating that " succinyl-cholin was the only aliphatic dibasic acid ester studied. Its action is similar to that of the valeryl compound." Unfortunately for Hunt and Taveaux the use of curarized animals in their experiments had prevented them from discovering the unique muscle relaxing properties of the substance.
It was not until 1949 that further interest was shown in suxamethonium. At this time Bovet, Bovet-Nitti, Guarino, Longo and Marotta were investigating the "Pharmacodynamic properties of some derivatives of benzoyl-choline having a curarizing action". They noted that suxamethonium produced muscle paralysis in dogs and rabbits, and related this to two factors. First, it consisted structurally of two molecules of acetylcholine joined together, and secondly, it contained two quaternary nitrogen atoms in a similar configuration to that seen in d-tubocurarine.
At the same time other workers (Phillips 1949, Buttle and Zaimis 1949) independently investigated suxamethonium and described its curarizing effects. Bovet-Nitti (1949) related the short duration of action of the drug to its rapid hydrolysis by plasma cholinesterase, an observation previously reported by Glick (1941) in his studies on the action of horse cholinesterase on suxamethonium.
The drug was introduced into clinical practice in the early 1950's following extensive studies carried out in experimental animals and human subjects in North America (Castillo and de Beer 1950), Continental Europe (Brucke et al. 1951 , Mayrhofer 1952 , Scandinavia (Thesleff 1952, von Dardel and Thesleff 1952) and the United Kingdom (Bourne, Collier and Somers 1952) .
The main properties of suxamethonium recorded by these early workers were its depolarizing effect on the neuromuscular junction, its short duration of action, and its low toxicity. They noted that it resembled acetylcholine or decamethonium in its mode of action rather than d-tubocurarine and that its paralysing effect, lasting about five minutes, was preceded by fasciculations.
They also recorded that doses 450 to 650 times the normal paralysing dose produced little toxic effect in artificially ventilated animals. This low toxicity was attributed to the relatively inert nature of suxamethonium (apart from its neuromuscular blocking effects) and to its rapid breakdown by cholinesterase to succinic acid and choline, which are normal components of metabolic pathways. Furthermore, no chronic toxic effects could be demonstrated by administering repeated sub-paralysing doses to experimental animals /).\\11) B. (;IIlH ovcr d pcriod of wcd:,.;. Otlll'r feature,; or ,;uxamethonium action recorded were slight bradycardia and llypertension, lack of tacltv-ph\"laxis, and prolongation of action in individuals with 10"" plasma cllOlinestcrase, or where an anticholinesterase had also beell administered.
On some minor points there was disagreement, and conflicting results were recorded regarding the effects of suxamethonium on histamine release, intestinal stimulation and ,;alivatioll. However, it was generally agreed that in normal clinical doses these effects were either ab,;ent or ,"ery small.
On the ba,;is of these studies suxalllethonium was recommended as the drug of choice for short anaesthetic procedures, such as endotracheal intubation, clectrocol1\"ubive therap\", oesophagoscop\" and orthopaedic manipulations where profound muscle relaxation was required" It was also used in the form of intermittent injection or continuous infusion for longer procedures, and good results were recorded.
Considerable difficulties exist in the testing and evaluation of am" new drug. Suxamethoniull1 SIIOWS great variation of action in different species (Paton and Zai11lis 1 H·!!), Foldes 1 HilH) and the results of animal experiments were frequentl~" not applicable in man. It is interesting to speculate, moreO\"er, that had boars \"ith geneticalh" determined predisposition to ll\"perpyrexia been used as experimental animals in the early stages of suxametlioniulll evaluation, the drug ma\" han' been abandoned as potentially too dangerous for use in man (Hall ct al. U)()()).
ST!<FClTI<E .\:\]) SV:\THE';b
Suxamethoniul11 ma\" be regarded as a condensation of two molecules of acetdcholinl', a dicholine ester of succinic acid, a ll1~tllOniulll compound or a substitution product of the hydrocarbon de cane ( Figure 1 )" This explains the large number of chemical names whicli have been used to describe its structure (Table I) . Its official names are Suxamethonium (RP.), Succinylcholine (U.s.P.) and Suxamethonii (I.P") (lVIerck Index, :\Iartindale\ Extra Pharmacopoeia)" The molecule exhibits features common to man\" other muscle relaxants, namel\" two quaternan" nitrogen atoms 1 .;") nm apart and separated b\" 10 interjacent atoms.
"arious methods of s\"nthesizing the drug ha\"" been described (Phillips 19J!J, ell' Beer ] Ho")!!, l\lerck Index). Basicalh", the\" consist of treating ~-dimcth\"laminoethan()l with a succin d compound (e.g" suecinyl chloride or diethdsuccinate) to product' dillll'tll\'lalltill();-;Uecillatl' \\lliell i;-; then Illethdated with a methd halicle. Suxamethoniunl is usually prepared as the h\'drated chloride or bromide, but other forms are availabk" The ciJemical and phy:-;ical propertic:-; of suxamdhonium cl Iloride dihydrate are sUlllmarized in Table~. It forms white odourless cn"stab with a salty taste. It is Yen" soluble in' water, moclerateh soluble in alc(;hol, and insoluble in ether. . In the cn"stalline form (U Anectine Flo-Pack" and ,,'Brevidil :\I") the drug is quite stable and will maintain its potenn' for \TarS, even 111 hot climates" "Brevidil }]" (suxal1lethoniul11 bromide dihydrate powder) is presented in an ampoule filled with nitrogen to prevent oxidation. .'\0 chemical stabilizers arc added to the powder.
The aqueou,; solutions (U Anectine" and " Scolinl''') hHlroh"se at an increasing rate as the pH, temperature and concentration of the solution rise. At a pH of ;{" il the il per cent solution is fair"" stable, and ma \" even he autoclan'cl at I~()O C for 10 mInutes \\"ithout .ll1l1cs/ilcsia IIlId 11l/fll.,il"l' Carl', ru/" J, Su. '!, .vUi'!'III/!I'/'. nli.·! SllXA~IETH());ll'~I-A REnEW III significant loss of potency, Alkaline solutions, on the other hand, rapidly lp,drolyse suxamethonium, Solutions of thiopentone sodium (pH 10·5), methohexitone sodium (pH 11), thiamylal sodiulll (pH 10 'R), hexobarbitone sodium and thialbarbitone sodium will reduce the potencv of suxamethonium bv more than ~o per cent in five minutes at room temperature. The use of mixed solutions of suxamethonium and intravenous barbiturates is not recommended. Not only is there a rapid loss of potency of the relaxant, but also there have been a number of reports of " awareness" of suxamethonium fasciculations following the use of such mixtures (Bourne et al. l!l;i:!, Dayies 1!W:)).
Although it had been shown that suxamethonium hydrolysis increased with increasing temperature (Earles ct al. 1954) , it was net until 1956 that reports of loss of potenc\ of suxamethonium solutions were received from tropical countries. Accounts of deterioration of suxamethonium in the West Indies ( Table 4 indicates the rates of hydrolysis for " Anectine" in relationship to temperature and aqueous concentration. ".-\nectine" contains no preservative or buffer and has a pH of 4·5.
The manufacturers recommend that suxamethonium chloride solution be stored at a temperature less than 4 0 C but above the freezing point of the solution. It should also be protected from light plartindale's Extra Pharmacopoeia HI (7) and stored in alkaline-free glass containers. Cnder these circumstances the ii per cent solution may IX' expected to retain its potency for over two \'ear,.;, .-\55.\ Y OF THE A\jCEOl'S Sou:TIo:\ The solution is assayed b\' neutralization with sodium hydroxide.' Aqueous-ether extraction is followed by the addition of a known amount of sodium hydroxide. Any remaining alkali is titrated with h~'drochloric acid using a bromo thymol blue indicator. Each millilitre of N f1 0 s'odium hydroxide used in the neutralization of the suxamethonium is equivalent to O'Ol!J87 gm of C14H30CI2N204·2H20. The solution should contain not less than 90 per cent nor more than 105 per cent of the dose stated on the lahel of the ampoule (British Pharmacopoeia) .
IDENTIFICATIOX A~D ESTII\IATIOK \\'hen suxamcthonium is in contact with blood and other bod\' fluid,.;, it is rapidly ll\'drolysed by cholinesterase, It is essential, tflcref(;re, tl1at an anticholinesterase (e,g. physostigmine) i,.; added to the,.;e samples as ,.;oon as they have heen taken in order to prevent loss of suxamethoniuIIl activih', \Vhen taken for toxicological purposes, such samples are treated with various solvents which extract the highh'
water-soluble and organic-solventinsoluble drugs which include suxamethonium, insulin and the gl ycosides.
Suxamethonium can be separated from this group by acidification, e\'aporation and methanol extraction (C1arke UW9).
\' arious methods llave been used for estimating levels of suxamethonium. These can be broadl\' classified into two categories: biological and ph ysico-chemical. Biological methods can be further subdivided into those employ'ing intact animals and those using muscle or nerve-muscle preparations.
Lethal dose (LD50) in mice, head drop (HD5o) in rabbits (Thesleff 1952), respiratory depression in rats (Salgado 19ti3), cat sciatic-gastrocnemius, pigeon pectoral muscle (Thesleff If);"):'!), rat diaphragm-phrenic ,llIaes/hesill {{lid 11I/l'lIsi,'(' ('111'1',1',,1, r, ,\' In potassium cadmium iodide solution suxamethonium forms long crystalline needles, while in potassium permanganate solution it forms irregular blades and needles. Paper and thin-layer chromatography can be employed to separate out suxamethonium, iodoplatinate spray being used as a localizing reagent. Infrared spectrophotometry using a potassium bromide disc gives the following principal peaks: A, 1724; B, 1148; and C, 1308 ( Figure 2 ). It is generally accepted that suxamethonium owes its short duration of action to the rapid hydrolysis facilitated by serum cholinesterase, This view, however, is not universally held, and a number of authors regard redistribution and binding as much more important factors in terminating suxamethonium action. Using 14C-suxamethonium in dogs, Dal Santo (1968) demonstrated that within five minutes of administration 80 per cent of the radioactivity had disappeared from plasma, indicating rapid extravascular redistribution. He also demonstrated plasma protein binding and noted that the l4C did not pass into the cerebrospinal fluid. The findings of Doenicke, Schmidinger and Krumey (1968) agree with Dal Santo's proposition that redistribution of suxamethonium through the extracellular fluids and binding to plasma protein and tissue cells are more important factors in the rapid termination of suxamethonium action than is enzymatic hydrolysis. Even the very existence of such hydrolysis is questioned by some. Using normal human plasma, Pilz and Horlein were unable to demonstrate this breakdown and they produced evidence that suxamethonium was saponified and metabolized by an enzyme in the lung (Doenicke et al. 1968 , Litwiller 1969 Suxamethonium is partially excreted unchanged in the urine. Norton and de Beer (1954) showed that the majority of cats and mice which they studied rapidly eliminated between 5 and 15 per cent of the administered dose of suxamethonium by renal excretion. There was a wide variation, however, and one cat in the series eliminated 46 per cent of the dose in this way. Dal Santo's dogs excreted 10 per cent of the administered 14C within five minutes of intravenous injection. The renal Anaesthesia and Intensive Care, Vol. J, No. :2, November, }97:2 11-1 D.\YIIl n. GIBB excretion of suxClllletl}()niulll in man is lo\\" and is quoted as between ~ and 10 per cent by various authors (Foldes, \. andervort and Shanor 1 HiI;), \\"ood-Smith, Stewart an(1 Yickers I !H;~, Knelle lH71h).
Suxamethoniulll Il\'drolysis 111 tl](' serum occurs in a two-stage reaction. Each of these stages is controlled by cholinesterase. The first stage reaction results in the formation of succinyllllonocholine, and this is then further brokeri. down into choline and succinic acid (see Figure 3 ). Doenicke et al. (Hlti8) explained Pilz's failure to demonstrate such hHlrolysis in vitro as being due to the use of high suxa-metllOniulll concentrations which caused complete inhibition of the enzymc. The initial reaction is between six and ten times faster inhihitioll in vitro at a suhstrate concentration of S -;", X 1O-,'1\\. Tbev werc also able to detect significant enzyme in'hibitioll in vivo following normal clinical doses of suxamethoniulll which result in a serum concentration of less than iI X 10-5 1\1. This inhibition was even more apparent 111 patients with abnormalh' lo\\" cholinesterase levels due to liver disease.
Succin \"ll1lonocholine differs from suxamethoniuln (succinylclicholine) in several respects. First, it has onl~" 2 per cent of the neuromuscular blocking effect of suxamethoniul1l (Lehmann and Silk 195:3) . ,\s it is more slowl\' clestro~"ed, its duration of action is longer and if ,;uxamethonium i,; given by infusion the drug \\'ill accumulate and mal' cause side-effects ,;nch as hi,;tamine release. Pnlike Sllxa-TAilLE ;j ~ 111 rlllliratioll of tlte Nates ofllvdmlvsis of. 1 cetl'lelwlilll', S1ICCillVllllOllocllOlil1C ami SlIxal/lcthoni1lJlI 1IIIder till' JII/luI'IICI' of .lcct\'lclwlinl'sil'rIlsl' IIwl Cholinesterllse, T0i!.cthfY than the second reaction. Tlm,; there is an accumulation of succindmonocholine. Both these reactions arc characterized by the fact that, above a critical substrate con~centration, the rate of hydrolysis is dependant only on enz\"me concentration. This indicates that abo've ,;uch a critical substrate concentration all the available enzyme sites arc saturated (Fulcles et al. IUilf), t'itwiller HHHl). The rate of hydrolysis in vitro using normal human plaslila at -pH 7 .. j and substrate concentration,; above the critical level is approximatel\' 2;) flg/min/ml of plasma.
The optimum pH for the reaction is ~-;") (Hunter In70). The ll\"drolysis is further complicated b\" the inhibition of cholinesterase which occurs a,; the concentration of suxamcthonium is increased. J)()enickc et al. (Hlf)S) demonstrated ;")0 per cent methonium, it can be hydroh"sed b\' acetdcholinesterase, and its inl;ibitol-\" effec~t on this enzyme is much less than that of suxametllOniulll (Ta'ble iI).
:'Ian y factors can alter the rate of ll\'drolysis of suxamethonium. The manner i11 wliich genetic constitution, exposure to ph~"sical or chemical agents, and disease proce,;ses can affect its hreakdown will he the suhject of a later paper. CHOL!:\,FSTEIL\SE III the hod v there are t\\"O enz\"mcs concerned with the br(:akdmvn of choline' esters. These have cOIllIll(JIllv been called "true cholinesterase" an'd "pseudocholinesterase" (Lehlllanll, Silk and Liddell J HilI, Lehmann and Liddell 1 !HiH). Because of growing confusion over the nomenclature and assav of enzvmes the International Union of Bio~hemistry set up an Enzyme Commission in 1955 to investigate this matter (King ]969), and in 1961 it put forward a report that was fully endorsed. It was decided that all enzymes would be classified by a code number, a systematic name and a trivial name. The code number consists of four digits. The first digit indicates the general enzyme type (e.g. transferase, hydrolase, etc.). The second digit indicates the chemical bonding involved in the reaction, the third the type of reaction, and the fourth the permanent identifying number of the enzyme within its sub-class.
The classification of the human "cholinesterases " is indicated in Table 6 . Throughout this review they will be referred to by their trivial names "acetylcholinesterase" and " cholinesterase ". Acetylcholinesterase is present at the neuromuscular junction, in nervous tissue, and in the red blood cell. It is specifically concerned with the breakdown of acetylcholine, which it hydrolyses at a much faster rate than any other choline ester. It does not hydrolyse suxamethonium to any appreciable extent. Its action on acetylcholine is inhibited by high concentration of acetylcholine or succinylmonocholine, by suxamethonium and by other choline esters, many of which may be found in the body (e.g. propionylcholine, butyrylcholine, etc.). Acetylcholinesterase contains two active sites for binding acetylcholine: an anionic site (probably a dissociated carboxyl group) where electrostatic binding with the quaternary nitrogen atoms occurs; and an esteratic site which forms a covalent linkage with the carbon atom of the carboxyl group. The choline portion is at first broken off, leaving an acetylated esteratic site which reacts with water, producing acetic acid and regenerating the enzyme (Koelle 1971a).
Cholinesterase is present in most tissues in the body, including plasma, nervous tissue, cardiac muscle, intestine and skin, but is not present in the red blood cells. It is formed in the liver and is capable of hydrolysing many different choline esters. Acetylcholine is broken down ~5 times as rapidly ·as suxamethoniull1. The mechanism of action of cholinesterase is thought to be similar to that of acetylcholinesterase ( Figure 4) and, although the existence of two active sites is disputed by some, its behaviour is biochemically compatible with the presence of two such sites (Lehmann and Liddell 1969) . The inhibition of cholinesterase bv choline esters is not as marked as that ~een with acetylcholinesterase.
In-vitro inhibition has, however, been demonstrated (Kalow and Davies 1958) .
Substances which inhibit cholinesterase fall into two main groups: those which uniformly depress the action of all cholinesterase variants and those which differentially inhibit such variants. With the exception of the organophosphates, which combine "irreversibly" to thl' l'~teratj(' ~itt,~, ll10st inhihitor~ arc of till' differential type. The vast majorit\' of these contain a positivel,,' charged nitrogen atom, combine at the anionic site ( Figure 4) , and inhibit the normal form of cholinesterase more than the abnormal form,.; (Kalow and Davies 195K, Lehmann and Liddell 19t39) . It is suggested that in the abnormal variants the anionic site is not as strongl,,' charged as in the normal enzyme and that this accounts for the differential' action. Table 7 lists some known cholinesterase inhibitors. Those substances which are used in the laborator\' to differentiate between cholinesterase variants are shown in the right-hand column. While most of the,.;e inhibit the normal form to a greater extent, n-butyl alcohol inhibits abnormal \'ariants and ,{ctivates the normal ('nz,·me.
to ani mal di~('as(',;. J nadi va tion of c hol i nesteraSl' in some cattle due to the ingestion of the naturaII\'-occurring anticholinesterases in white clover and solanaceous plants may give rise to the disease "bloat" (Lehmann, Silk and LiddeII 19tH) .
The occurrence of a variet\' of forms of cholinesterase has some interesting genetic implications.
The site on the chromosomes which determines the production of cholinesterase rn,l\' be occupied b\' two genes which may be normal or consist of combinations of the' normal and abnormal genes. The abnormal genes were first detected when the use of suxamethonium produced unusually long periods of paralysis in susceptible individuals. The high incidence of the normal homoz,,'gote indicates that this confers great advantage, while the 
Pethidine
Human cholinesterase is an acid gl\'coprotei 11 containing several residues per molecule of scialic acid (a derivative of neuraminic acid). Its exact molecular weight is not known, but has been reported as between WS,OOO and :~O(),O()() (Litwiller 19fHJ).
On paper electrophoresis it migrates \"it!! the :x~-globulins (at pH 8 ·9) or the ~-gl()hulins (pH !l'7) (Liddell et al. 196'2) .
The exact function of cholinesterase IS unknown, and some apparenth' healthy individuals ma\' inherit Yen' low levels of tile enzyme. This -ma',' only -become apparent if tbe individual is challenged by a drug such as suxamethonium. It has been postulated that the function of cholinesterase is to destroy esters such as propionylcholine and butvryicholine which ma \' inhibit acetylcllOlinestcrase and thus lead to neuromuscular' and autonomic d\'sfunction. Such compounds ma',' be produced a,.; metabolic In'-products of acet,,'lcholine s\'nthesi~ and 1)\' bacterial action 111 the iilt('stine~. This thcor\' is supported h\' referencE' (and other alkyl a lcohols) low incidence of abnormal hO\1loz\'gotes indicates a distinct disadvantage in natural selection. Polymorphism (which occurs in the heterozygous state) generaIl~' arises as a result of the balance of the advantages conferred by the allelic genes. The abnormal forms of cholinesterase are resistant to man V cholinesterase inhibitors, and it i~ proposed tliat the heterozygote offers the dual advantages of adequate hydrolysis of choline esters and resistance to enz\'mc inhibitors.
CHOLl:\ESTER.\SE .\SSAY .\ number of methods of estimation of cilOlinesterase levels in serum have been devised (Stovner and Lund 1970, Hunter 1970) . Lack of unifonnih' in the methods used ha\'e led to consideralJle difficult\· in interpreting the results of such estimations. The main variables in the commonlv used assa\'s are substrates u~ed and their concentrations-, the temperature and pH at which the assa\' i~ carried out, and tIlt' method of expressing the results (Hunter 
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Acetylcholine 20 0 C Davidson and Griffith (1961) ("Acholest")
Johnson and
Acetylcholine 37 0 C Whitehead (1965) Merck-s-butyryl-25 0 C I-Test thiocholine pH 7.7 iodide 1!J70). technical information on their proprietary preparations of suxamethonium.
